Skip to content
ContentLora

    Tip: press / anywhere to search.

    Explainer

    Kratom and 7-OH explained: risks, legal status and DEA scheduling

    Kratom is a Southeast Asian tree whose leaves can produce opioid-like and stimulant-like effects; it is sold widely in the US but FDA has approved no use for it.[1][2][3] 7-OH is a minor kratom alkaloid with much stronger opioid-receptor potency, now sold in concentrated products; FDA asked DEA to schedule it in July 2025.[4][5] In October 2026 DEA issued a notice of intent to temporarily place 7-OH above a set threshold in Schedule I.[6]

    Editor reviewedStrict sourcingUpdated Explainer24 claims · 100% primaryDrugs, alcohol and addiction, Health and medicine

    This page is general information, not medical advice. It does not give amounts or instructions for use. If you use kratom or 7-OH and want to stop, or are worried about withdrawal, talk to a clinician.

    For confidential help with substance use, call the SAMHSA National Helpline at 1-800-662-HELP (4357) or visit FindTreatment.gov.[7] For a possible poisoning, US poison control is 1-800-222-1222; in an emergency, call 911.[8]

    Kratom is a plant product sold in the US online and in stores.[1] Since 2025 federal regulators have focused on concentrated products made from one of its compounds, 7-hydroxymitragynine (7-OH), rather than on natural kratom leaf.[5] This page explains both, what is known about their risks, and where federal action stands.

    What kratom is

    Kratom (Mitragyna speciosa) is a tropical tree native to Southeast Asia, and products made from its leaves are sold in the US online and in stores.[1] NIDA says kratom can produce both opioid-like and stimulant-like effects.[2] About 1.7 million Americans aged 12 and older used it in 2021, according to the National Survey on Drug Use and Health.[9]

    People report using kratom to self-treat pain, anxiety, depression, opioid use disorder and opioid withdrawal.[3] FDA has approved no use for kratom, and no kratom drug products are legally marketed.[3][10] NIDA says much is still unknown about kratom’s short- and long-term health and safety effects, and it supports research on kratom’s potential medicinal uses.[11]

    Known risks of kratom

    FDA warns consumers not to use kratom because of the risk of serious adverse events, including liver toxicity, seizures and substance use disorder.[12] Deaths have been associated with kratom in rare cases, but FDA and NIDA say nearly all involved other drugs or contaminants, so kratom’s own contribution is unclear.[13] FDA is also aware of newborns showing withdrawal signs (neonatal abstinence syndrome) after prolonged kratom exposure before birth, and has warned about products contaminated with Salmonella or heavy metals.[14]

    What 7-OH is and why regulators focus on it

    7-OH occurs naturally in kratom, but makes up less than 2% of the leaf’s alkaloids.[4] FDA says it has substantially greater mu-opioid receptor potency than mitragynine, kratom’s main alkaloid, and than morphine.[4] DEA notes that 7-OH can be made from mitragynine in a one-step chemical reaction.[15]

    FDA said in July 2025 that concentrated 7-OH products were easy to buy online and in gas stations, corner stores and vape shops, including forms such as fruit-flavored gummies and ice cream cones that may appeal to children.[16] There are no FDA-approved 7-OH drugs, and 7-OH is not lawful in dietary supplements or conventional foods.[17] DEA has cited 165 poison center exposure cases involving 7-OH from January to July 2025; among cases involving 7-OH alone, 35% resulted in serious health problems.[18]

    Federal and state action

    DateAction
    June 2025FDA sends warning letters to seven companies selling 7-OH products[16]
    29 Jul 2025FDA recommends scheduling certain 7-OH products, not natural kratom leaf[5]
    Jul 2026DEA notice of intent to temporarily schedule 7-OH above a threshold[19]
    26 Aug 2026Temporary order puts three related compounds, including mitragynine pseudoindoxyl, in Schedule I until August 2028[20]
    14 Oct 2026DEA withdraws the July notice and issues a new one, with a threshold recommended by HHS on 8 October[6]

    DEA, not FDA, has the final say on scheduling.[21] The October 2026 notice covers 7-OH and mitragynine pseudoindoxyl above a specified threshold; DEA said the threshold would let some products stay on sale but that neither it nor HHS had found below-threshold levels safe.[6] The Schedule I controls would apply once DEA issues the temporary order itself.[22]

    FDA said its 7-OH recommendation was not focused on natural kratom leaf products, and NIDA says kratom products remain legal in many areas while agencies review the evidence.[5][23] States vary: DEA notes that 19 states have passed Kratom Consumer Protection Act model laws, and some cap 7-OH as a share of total alkaloids.[24] FDA separately says kratom cannot lawfully be sold as a drug, dietary supplement or food additive.[10]

    Federal scheduling of 7-OH was still in progress when this page was written. Check the Federal Register for whether DEA has issued the temporary order.

    Next in the crash course

    More in Drugs & addiction

    Questions readers ask

    What is kratom?

    Kratom (Mitragyna speciosa) is a tropical tree native to Southeast Asia. Products made from its leaves are sold in the US online and in stores, and NIDA says they can produce both opioid-like and stimulant-like effects.[1][2]

    What is 7-OH?

    7-hydroxymitragynine (7-OH) is a naturally occurring kratom alkaloid that makes up less than 2% of the leaf's alkaloids. FDA says it is far more potent at opioid receptors than kratom's main alkaloid, and DEA says it can be made from that alkaloid in a one-step chemical reaction.[4][15]

    Is kratom legal?

    NIDA says kratom products are currently legal in many areas. FDA says kratom cannot lawfully be sold as a drug, dietary supplement or food additive, and some states regulate it.[23][10][24]

    Is 7-OH being banned?

    FDA recommended scheduling 7-OH in July 2025. On 14 October 2026 DEA issued a notice of intent to temporarily place 7-OH and a related compound above a specified threshold in Schedule I; the controls apply once a temporary order is issued.[5][6][22]

    What are the risks of kratom?

    FDA warns of serious adverse events including liver toxicity, seizures and substance use disorder. A small number of deaths have been associated with kratom, nearly all involving other drugs or contaminants.[12][13]

    Can kratom treat opioid withdrawal?

    People report using kratom to self-treat opioid withdrawal and opioid use disorder, but FDA has approved no use for kratom and no kratom drug products are legally on the market.[3][10]

    Sources

    · 24 claims from 3 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      Kratom (Mitragyna speciosa) is a tropical tree native to Southeast Asia whose leaf products are sold in the US online and in stores. confirmedas of 2026-11-07

      • FDA and Kratom · U.S. Food and Drug Administration · Primary source · Introduction (retrieved 2026-11-07)
    2. [2]

      NIDA says kratom can produce both opioid-like and stimulant-like effects. confirmedas of 2026-11-07

      • Kratom · National Institute on Drug Abuse · Primary source · Highlights (retrieved 2026-11-07)
    3. [3]

      People report using kratom to self-treat pain, anxiety, depression, opioid use disorder and opioid withdrawal, though FDA has approved no use for kratom. confirmedas of 2026-11-07

      • FDA and Kratom · U.S. Food and Drug Administration · Primary source · Introduction (retrieved 2026-11-07)
      • Kratom · National Institute on Drug Abuse · Primary source · Highlights (retrieved 2026-11-07)
    4. [4]

      7-hydroxymitragynine (7-OH) occurs naturally in kratom but makes up less than 2% of the leaf's alkaloids, and FDA says it has substantially greater mu-opioid receptor potency than mitragynine and than morphine. confirmedas of 2026-11-07

      • FDA and Kratom · U.S. Food and Drug Administration · Primary source · Introduction (retrieved 2026-11-07)
      • FDA and Kratom · U.S. Food and Drug Administration · Primary source · Introduction (retrieved 2026-11-07)
    5. [5]

      On 29 July 2025 FDA recommended scheduling certain 7-OH products under the Controlled Substances Act, saying it was targeting concentrated 7-OH and not natural kratom leaf products. confirmedas of 2026-11-07

    6. [6]

      After an 8 October 2026 HHS letter recommending a new threshold, DEA on 14 October 2026 withdrew its July notice and issued a new notice of intent to temporarily schedule 7-OH and mitragynine pseudoindoxyl above that threshold, saying the threshold would let certain products stay on the market but that neither agency had found below-threshold levels safe. confirmedas of 2026-11-07

    7. [7]

      The SAMHSA National Helpline, 1-800-662-HELP (4357), and FindTreatment.gov give US referrals to substance use and mental health treatment programs. confirmedas of 2026-11-07

      • Research Topics · National Institute on Drug Abuse · Primary source · In an emergency? Need treatment? (retrieved 2026-11-07)
    8. [8]

      In the US, poison control can be reached at 1-800-222-1222, and people in immediate danger should call 911. confirmedas of 2026-11-07

      • Research Topics · National Institute on Drug Abuse · Primary source · In an emergency? Need treatment? (retrieved 2026-11-07)
      • Research Topics · National Institute on Drug Abuse · Primary source · In an emergency? Need treatment? (retrieved 2026-11-07)
    9. [9]

      About 1.7 million Americans aged 12 and older used kratom in 2021, according to the National Survey on Drug Use and Health as cited by FDA. confirmedas of 2026-11-07

      • FDA and Kratom · U.S. Food and Drug Administration · Primary source · Introduction (retrieved 2026-11-07)
    10. [10]

      FDA says no kratom drug products are legally on the US market and that kratom cannot lawfully be sold as a dietary supplement or added to conventional food. confirmedas of 2026-11-07

      • FDA and Kratom · U.S. Food and Drug Administration · Primary source · Introduction (retrieved 2026-11-07)
      • FDA and Kratom · U.S. Food and Drug Administration · Primary source · Introduction (retrieved 2026-11-07)
    11. [11]

      NIDA says much is still unknown about the short- and long-term health and safety effects of kratom, and it supports and conducts research on kratom's potential medicinal uses. confirmedas of 2026-11-07

      • Kratom · National Institute on Drug Abuse · Primary source · What is kratom? (retrieved 2026-11-07)
      • Kratom · National Institute on Drug Abuse · Primary source · Highlights (retrieved 2026-11-07)
    12. [12]

      FDA warns consumers not to use kratom because of the risk of serious adverse events including liver toxicity, seizures and substance use disorder. confirmedas of 2026-11-07

      • FDA and Kratom · U.S. Food and Drug Administration · Primary source · What can happen if a person uses kratom? (retrieved 2026-11-07)
    13. [13]

      FDA and NIDA say a small number of deaths have been associated with kratom, nearly all involving other drugs or contaminants, so kratom's contribution is unclear. confirmedas of 2026-11-07

      • FDA and Kratom · U.S. Food and Drug Administration · Primary source · What can happen if a person uses kratom? (retrieved 2026-11-07)
      • Kratom · National Institute on Drug Abuse · Primary source · Highlights (retrieved 2026-11-07)
    14. [14]

      FDA is aware of neonatal abstinence syndrome cases after prolonged kratom exposure before birth and has warned about kratom products contaminated with Salmonella or heavy metals. confirmedas of 2026-11-07

      • FDA and Kratom · U.S. Food and Drug Administration · Primary source · What can happen if a person uses kratom? (retrieved 2026-11-07)
      • FDA and Kratom · U.S. Food and Drug Administration · Primary source · What can happen if a person uses kratom? (retrieved 2026-11-07)
    15. [15]

      DEA says 7-OH can be made from mitragynine, kratom's main alkaloid, in a one-step chemical reaction. confirmedas of 2026-11-07

    16. [16]

      FDA said concentrated 7-OH products were sold online and in gas stations, corner stores and vape shops, including forms that may appeal to children such as fruit-flavored gummies, and in June 2025 it sent warning letters to seven companies. confirmedas of 2026-11-07

    17. [17]

      FDA says there are no FDA-approved 7-OH drugs, and 7-OH is not lawful in dietary supplements or conventional foods. confirmedas of 2026-11-07

    18. [18]

      DEA cited 165 poison center exposure cases involving 7-OH from January to July 2025; among cases involving 7-OH alone, 35% resulted in serious health problems. confirmedas of 2026-11-07

    19. [19]

      In July 2026 DEA published a notice of intent to temporarily place 7-OH above a specified threshold in Schedule I. confirmedas of 2026-11-07

    20. [20]

      A DEA temporary order placed three 7-OH-related substances, mitragynine pseudoindoxyl, MGM-15 and MGM-16, in Schedule I from 26 August 2026 until 26 August 2028. confirmedas of 2026-11-07

    21. [21]

      DEA, not FDA, has final authority over scheduling, through a rulemaking that includes a public comment period. confirmedas of 2026-11-07

    22. [22]

      DEA's October 2026 document is a notice of intent; the Schedule I controls on 7-OH above the threshold would apply once a temporary order is issued. confirmedas of 2026-11-07

    23. [24]

      DEA notes that 19 states have enacted Kratom Consumer Protection Act model legislation, and some states cap 7-OH as a share of total alkaloid content. confirmedas of 2026-11-07

    Revision history (1)
    1. Page created.

    Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: Jan 7, 2027.

    Cite this page

    "Kratom and 7-OH explained: risks, legal status and DEA scheduling." ContentLora, updated Nov 7, 2026. https://contentlora.com/explain/kratom-and-7-oh-explained

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.